search
Back to results

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE)

Primary Purpose

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
bavituximab
Docetaxel
Placebo (for bavituximab)
Sponsored by
Peregrine Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Small-Cell Lung Cancer Stage IIIB focused on measuring SUNRISE, PPHM 1202, Bavituximab, Peregrine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Male or female at least 18 years of age
  • Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)
  • Radiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy. For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment should have been used. Mutation testing is not required.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate hematologic, renal and hepatic function

Exclusion Criteria:

  • Squamous, small cell, carcinoid, adenosquamous, large-cell neuroendocrine, or mixed histology containing small-cell or squamous-cell NSCLC
  • Known history of bleeding disorders, eg, von Willebrand disease or hemophilia
  • Cavitary tumors or tumors invading or abutting large blood vessels
  • Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the 6 months before screening
  • Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening
  • Grade 2 or higher peripheral neuropathy

Sites / Locations

  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site
  • Peregrine Pharmaceuticals Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

bavituximab plus docetaxel

placebo plus docetaxel

Arm Description

Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.

Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.

Outcomes

Primary Outcome Measures

Overall Survival

Secondary Outcome Measures

Progression-free survival
Overall Response Rate
Safety
As measured by adverse event rates and laboratory evaluations

Full Information

First Posted
November 25, 2013
Last Updated
April 19, 2017
Sponsor
Peregrine Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT01999673
Brief Title
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
Acronym
SUNRISE
Official Title
SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
December 2013 (undefined)
Primary Completion Date
March 2017 (Actual)
Study Completion Date
March 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peregrine Pharmaceuticals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV, Non-Small-Cell Lung Cancer Metastatic, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, Nonsmall Cell Lung Cancer
Keywords
SUNRISE, PPHM 1202, Bavituximab, Peregrine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
582 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
bavituximab plus docetaxel
Arm Type
Experimental
Arm Description
Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
Arm Title
placebo plus docetaxel
Arm Type
Placebo Comparator
Arm Description
Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
Intervention Type
Biological
Intervention Name(s)
bavituximab
Intervention Type
Drug
Intervention Name(s)
Docetaxel
Other Intervention Name(s)
Taxotere
Intervention Type
Other
Intervention Name(s)
Placebo (for bavituximab)
Primary Outcome Measure Information:
Title
Overall Survival
Time Frame
Approximately up to 36 months
Secondary Outcome Measure Information:
Title
Progression-free survival
Time Frame
Approximately up to 36 months
Title
Overall Response Rate
Time Frame
Approximately up to 36 months
Title
Safety
Description
As measured by adverse event rates and laboratory evaluations
Time Frame
Approximately up to 36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Male or female at least 18 years of age Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition) Radiographic disease recurrence or progression during or after front-line platinum-based doublet chemotherapy. For patients with known epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) translocations, appropriate targeted treatment should have been used. Mutation testing is not required. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate hematologic, renal and hepatic function Exclusion Criteria: Squamous, small cell, carcinoid, adenosquamous, large-cell neuroendocrine, or mixed histology containing small-cell or squamous-cell NSCLC Known history of bleeding disorders, eg, von Willebrand disease or hemophilia Cavitary tumors or tumors invading or abutting large blood vessels Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the 6 months before screening Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months of screening Grade 2 or higher peripheral neuropathy
Facility Information:
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Huntsville
State/Province
Alabama
ZIP/Postal Code
35805
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Chandler
State/Province
Arizona
ZIP/Postal Code
85224
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Glendale
State/Province
Arizona
ZIP/Postal Code
85306
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Greenbrae
State/Province
California
ZIP/Postal Code
94904
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Oceanside
State/Province
California
ZIP/Postal Code
92056
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
West Hills
State/Province
California
ZIP/Postal Code
91307
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Fort Myers
State/Province
Florida
ZIP/Postal Code
33916
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33705
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Athens
State/Province
Georgia
ZIP/Postal Code
30607
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Savannah
State/Province
Georgia
ZIP/Postal Code
31404
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46254
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Marrero
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71101
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Frederick
State/Province
Maryland
ZIP/Postal Code
21701
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68506
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Lebanon
State/Province
New Hampshire
ZIP/Postal Code
03756
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45242
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Middletown
State/Province
Ohio
ZIP/Postal Code
45042
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97213
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37909
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37323
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Abilene
State/Province
Texas
ZIP/Postal Code
79606
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75201
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Temple
State/Province
Texas
ZIP/Postal Code
76508
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98108
Country
United States
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Campbelltown
State/Province
New South Wales
ZIP/Postal Code
2560
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Tweed Heads
State/Province
New South Wales
ZIP/Postal Code
2485
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Milton
State/Province
Queensland
ZIP/Postal Code
4064
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Redcliffe
State/Province
Queensland
ZIP/Postal Code
4020
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Elizabeth Vale
State/Province
South Australia
ZIP/Postal Code
5112
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Toorak Gardens
State/Province
South Australia
ZIP/Postal Code
5065
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Geelong
State/Province
Victoria
ZIP/Postal Code
3220
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Wodonga
State/Province
Victoria
ZIP/Postal Code
3690
Country
Australia
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Antwerp
ZIP/Postal Code
2020
Country
Belgium
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Bruxelles
ZIP/Postal Code
1000
Country
Belgium
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Gent
ZIP/Postal Code
9000
Country
Belgium
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Herstal
ZIP/Postal Code
4040
Country
Belgium
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Liege
ZIP/Postal Code
4000
Country
Belgium
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Mechelen
ZIP/Postal Code
2800
Country
Belgium
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Namur
ZIP/Postal Code
5000
Country
Belgium
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Marseille
State/Province
Bouches-du-Rhone
ZIP/Postal Code
13273
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Caen
State/Province
Calvados
ZIP/Postal Code
14076
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Brest
State/Province
Finistere
ZIP/Postal Code
29609
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Nantes
State/Province
Loire-Atlantique
ZIP/Postal Code
44202
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Nancy
State/Province
Meurthe-et-Moselle
ZIP/Postal Code
54100
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Bayonne
State/Province
Pyrenees-Atlantiques
ZIP/Postal Code
64100
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Saint Priest en Jarez
ZIP/Postal Code
42271
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Saint-Herblain
ZIP/Postal Code
44805
Country
France
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Karlsruhe
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
76137
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Munchen
State/Province
Bayern
ZIP/Postal Code
81675
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Immenhausen
State/Province
Hessen
ZIP/Postal Code
34376
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Marburg
State/Province
Hessen
ZIP/Postal Code
35043
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Koln
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
51109
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Erfurt
State/Province
Thuringia
ZIP/Postal Code
99089
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Berlin
ZIP/Postal Code
12200
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Berlin
ZIP/Postal Code
13125
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Grosshansdorf
ZIP/Postal Code
22927
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Halle an der Saale
ZIP/Postal Code
06120
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Hamburg
ZIP/Postal Code
21075
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Kassel
ZIP/Postal Code
34125
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Munster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Villingen-Schwenningen
ZIP/Postal Code
78052
Country
Germany
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Patras
State/Province
Achaia
ZIP/Postal Code
26500
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Neo Faliro
State/Province
Athens
ZIP/Postal Code
18547
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Athens
State/Province
Attiki
ZIP/Postal Code
12464
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Chania
State/Province
Crete
ZIP/Postal Code
73300
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Heraklion
State/Province
Irakleio
ZIP/Postal Code
71110
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Thermi
State/Province
Thessaloniki
ZIP/Postal Code
57001
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Athens
ZIP/Postal Code
11527
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Larissa
ZIP/Postal Code
41110
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Thessaloniki
ZIP/Postal Code
56429
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Budapest
ZIP/Postal Code
1121
Country
Hungary
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Budapest
ZIP/Postal Code
1125
Country
Hungary
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Gyor
ZIP/Postal Code
9023
Country
Hungary
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Gyula
ZIP/Postal Code
5703
Country
Hungary
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Szolnok
ZIP/Postal Code
5004
Country
Hungary
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Torokbalint
ZIP/Postal Code
2045
Country
Hungary
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Zalaegerszeg
ZIP/Postal Code
8900
Country
Hungary
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Meldola
State/Province
Forli-Cesena
ZIP/Postal Code
47014
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Lido di Camaiore
State/Province
Lucca
ZIP/Postal Code
55041
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Taormina
State/Province
Messina
ZIP/Postal Code
98039
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Monza
State/Province
Monza Brianza
ZIP/Postal Code
20900
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Aviano
State/Province
Pordenone
ZIP/Postal Code
33081
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Bergamo
ZIP/Postal Code
24127
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Cremona
ZIP/Postal Code
26100
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Milan
ZIP/Postal Code
20162
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Turin
ZIP/Postal Code
10126
Country
Italy
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Suwon
State/Province
Gyeonggi-do
ZIP/Postal Code
443-380
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Suwon
State/Province
Gyonggi-do
ZIP/Postal Code
442-723
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Busan
ZIP/Postal Code
602-702
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Cheongju-si
ZIP/Postal Code
361711
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Incheon
ZIP/Postal Code
400-711
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Seongnam
ZIP/Postal Code
463-707
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Seoul
ZIP/Postal Code
137-701
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Seoul
ZIP/Postal Code
156707
Country
Korea, Republic of
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Brasov
ZIP/Postal Code
500091
Country
Romania
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Cluj-Napoca
ZIP/Postal Code
400058
Country
Romania
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Cluj-Napoca
ZIP/Postal Code
400349
Country
Romania
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Ploiesti
ZIP/Postal Code
100337
Country
Romania
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Suceava
ZIP/Postal Code
720237
Country
Romania
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Turda
ZIP/Postal Code
401103
Country
Romania
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Ekaterinburg
ZIP/Postal Code
620036
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Kursk
ZIP/Postal Code
305035
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Nizhny Novgorod
ZIP/Postal Code
603081
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Obninsk
ZIP/Postal Code
249036
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
St. Petersburg
ZIP/Postal Code
194291
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
St. Petersburg
ZIP/Postal Code
197022
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
St. Petersburg
ZIP/Postal Code
197758
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Yaroslavl
ZIP/Postal Code
150054
Country
Russian Federation
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Hospitalet de Llobregat
State/Province
Barcelona
ZIP/Postal Code
08908
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Manresa
State/Province
Barcelona
ZIP/Postal Code
08243
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Majadahonda
State/Province
Madrid
ZIP/Postal Code
28222
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
A Coruna
ZIP/Postal Code
15006
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Valencia
ZIP/Postal Code
46017
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Kaohsiung City
ZIP/Postal Code
833
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Putzu
ZIP/Postal Code
613
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Taichung
ZIP/Postal Code
402
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Tainan City
ZIP/Postal Code
736
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Taipei
ZIP/Postal Code
10449
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Taipei
ZIP/Postal Code
112
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Taoyuan
ZIP/Postal Code
333
Country
Taiwan
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Chernivtsi
ZIP/Postal Code
58013
Country
Ukraine
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Dnipropetrovsk
ZIP/Postal Code
49102
Country
Ukraine
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Khmelnytskyi
ZIP/Postal Code
29009
Country
Ukraine
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Kyiv
ZIP/Postal Code
03115
Country
Ukraine
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Lutsk
ZIP/Postal Code
43018
Country
Ukraine
Facility Name
Peregrine Pharmaceuticals Investigational Site
City
Uzhgorod
ZIP/Postal Code
88000
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
29767677
Citation
Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.
Results Reference
derived

Learn more about this trial

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

We'll reach out to this number within 24 hrs